![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by sdb on February 25, 2010, at 9:52:49
fish oil works for a better lipid profile and flexible erythrocytes but is this still used in the psychiatry and how does it work?
Posted by SLS on February 26, 2010, at 10:19:07
In reply to fish oil, still used or is it outdate ?, posted by sdb on February 25, 2010, at 9:52:49
> fish oil works for a better lipid profile and flexible erythrocytes but is this still used in the psychiatry and how does it work?
A recent study (Severus et al.) demonstrated that intravenous administration of fish oil produced a rapid antidepressant response in bipolar depression. Improvements were observed within the first three days.
- Scott
Posted by Netch on March 1, 2010, at 8:25:49
In reply to Re: fish oil, still used or is it outdate ?, posted by SLS on February 26, 2010, at 10:19:07
Recent meta-study found benefits:
Updated systematic review and meta-analysis of the effects of n3 long-chain polyunsaturated fatty acids on depressed mood
Background: The debate over a role for n3 long-chain polyunsaturated fatty acids (n3 PUFAs) in depressed mood continues.
Objective: The objective was to update a previous systematic review and meta-analysis of published randomized controlled trials investigating the effects of n3 PUFAs on depressed mood and to explore potential sources of heterogeneity.
Design: Eight databases were searched for trials that randomly assigned participants to receive n3 PUFAs/fish, measured depressed mood, used human participants, and included a comparison group up to April 2009.
Results: Thirty-five randomized controlled trials were identified; 17 were not included in the previous review. The pooled standardized difference in mean outcome of the 29 trials that provided data to allow pooling (fixed-effects model) was 0.10 SD (95% CI: 0.02, 0.17) in those who received n3 PUFAs compared with placebo, with strong evidence of heterogeneity (I2 = 65%, P < 0.01). The presence of funnel plot asymmetry suggested that publication bias was a likely source of this heterogeneity. Depressive symptom severity and participant diagnosis also explained some of the observed heterogeneity. Greater effects of n3 PUFAs were found in individuals with more-severe depressive symptoms. In trials that enrolled individuals with a diagnosed depressive disorder, the combined mean difference was 0.41 (95% CI: 0.26, 0.55), although evidence of heterogeneity was also found (I2 = 71%). In trials that enrolled individuals without a depressive diagnosis, no beneficial effects of n3 PUFAs were found (largest combined mean difference: 0.22; 95% CI: 0.01, 0.44; I2 = 0%).
Conclusions: Trial evidence of the effects of n3 PUFAs on depressed mood has increased but remains difficult to summarize because of considerable heterogeneity. The evidence available provides some support of a benefit of n3 PUFAs in individuals with diagnosed depressive illness but no evidence of any benefit in individuals without a diagnosis of depressive illness.
This is the end of the thread.
Psycho-Babble Alternative | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.